AustralieFrV1, PascalFrancis, Corpus, bibRecord, 003363

Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study

Identifieur interne : 003363 ( PascalFrancis/Corpus ); précédent : 003362; suivant : 003364

Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study

Auteurs : Oluf Dimitri Roe ; Jenette Creaney ; Steinar Lundgren ; Erik Larsson ; Helmut Sandeck ; Paolo Boffetta ; Tom Ivar Nilsen ; Bruce Robinson ; Kristina Kjaerheim

Source :

Lung cancer [ 0169-5002 ] ; 2008.

RBID : Pascal:08-0401056

Descripteurs français

Pascal (Inist)
- Mésothéliome malin, Pathologie de l'appareil respiratoire, Facteur prédictif, Pronostic, Etude cas témoin, Immunohistochimie, Marqueur tumoral, Cancérologie, Pneumologie.

English descriptors

KwdEn :
- Cancerology, Case control study, Immunohistochemistry, Malignant mesothelioma, Pneumology, Predictive factor, Prognosis, Respiratory disease, Tumoral marker.

Abstract

Soluble mesothelin-related protein (SMRP) in serum is potentially a sensitive marker of malignant mesothelioma (MM) diagnosis and progression, and may be useful as screening marker. Mesothelin expression in tumors is regarded as a sensitive marker for diagnosis and disease progression, and is a candidate prognostic marker. Levels of SMRP, CA125 and CYFRA 21-1 in pre-diagnostic (1-30 years) serum samples from 47 mesothelioma cases and 141 matched controls were analysed. Mesothelin expression in tumors was assessed. The association between biomarker level and mesothelioma risk and survival was analysed, adjusting for asbestos exposure. Survival related to tumor mesothelin expression, age, sex, histological type, location, asbestos exposure and pre-clinical SMRP was analysed. There was no significant association between biomarker levels and mesothelioma risk when analysed as continuous variables or as tertiles. Biomarker levels <10, 10-19 and ≥20 years before diagnosis were not significantly associated to mesothelioma risk. Mesothelin expressed in >50% of tumor cells was seen in 36 of 47 (77%) tumors. Mesothelin expression in <50% of tumor cells was a significant negative prognostic marker in all cases of malignant mesothelioma (median survival=6 months vs. 12 months, hazard ratio (HR)=2.49, 95%CI 1.17-5.27), and also when only epithelial mesothelioma was analysed (median =6 months vs. 14 months, HR=2.36, 95%CI 1.07-5.22). When adjusted for age and gender, the prognosis was still dismal, but non-significant (HR=1.85, 95%CI 0.85-4.05). High age (>65 years) was an independent negative prognostic factor that was related to both mesothelin expression and asbestos exposure. Mesothelioma of the epithelial type of the peritoneum had a significantly longer survival than epithelial type in pleura and was also related to mesothelin expression.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0169-5002`
A02	`01`			`@0 LUCAE5`
A03		`1`		`@0 Lung cancer`
A05				`@2 61`
A06				`@2 2`
A08	`01`	`1`	`ENG`	`@1 Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study`
A11	`01`	`1`		`@1 ROE (Oluf Dimitri)`
A11	`02`	`1`		`@1 CREANEY (Jenette)`
A11	`03`	`1`		`@1 LUNDGREN (Steinar)`
A11	`04`	`1`		`@1 LARSSON (Erik)`
A11	`05`	`1`		`@1 SANDECK (Helmut)`
A11	`06`	`1`		`@1 BOFFETTA (Paolo)`
A11	`07`	`1`		`@1 NILSEN (Tom Ivar)`
A11	`08`	`1`		`@1 ROBINSON (Bruce)`
A11	`09`	`1`		`@1 KJAERHEIM (Kristina)`
A14	`01`			`@1 Department of Oncology, St. Olavs Hospital, Trondheim University Hospital @3 NOR @Z 1 aut. @Z 3 aut.`
A14	`02`			`@1 Norwegian University of Science and Technology (NTNU), Department of Cancer Research and Molecular Medicine @2 Trondheim @3 NOR @Z 1 aut. @Z 3 aut.`
A14	`03`			`@1 School of Medicine and Pharmacology, University of Western Australia, QfEII Medical Centre Nedlands @2 Perth, Western Australia @3 AUS @Z 2 aut. @Z 8 aut.`
A14	`04`			`@1 Norwegian University of Science and Technology (NTNU), Department of Laboratory Medicine, Children's and Women's Health @2 Trondheim @3 NOR @Z 4 aut.`
A14	`05`			`@1 Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim University Hospital @3 NOR @Z 5 aut.`
A14	`06`			`@1 International Agency for Research on Cancer @2 Lyon @3 FRA @Z 6 aut.`
A14	`07`			`@1 Norwegian University of Science and Technology (NTNU), Human Movement Science Programme @3 NOR @Z 7 aut.`
A14	`08`			`@1 The Cancer Registry of Norway @2 Oslo @3 NOR @Z 9 aut.`
A20				`@1 235-243`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 21159 @5 354000196288910130`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 65 ref.`
A47	`01`	`1`		`@0 08-0401056`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Lung cancer`
A66	`01`			`@0 IRL`
C01	`01`		`ENG`	@0 Soluble mesothelin-related protein (SMRP) in serum is potentially a sensitive marker of malignant mesothelioma (MM) diagnosis and progression, and may be useful as screening marker. Mesothelin expression in tumors is regarded as a sensitive marker for diagnosis and disease progression, and is a candidate prognostic marker. Levels of SMRP, CA125 and CYFRA 21-1 in pre-diagnostic (1-30 years) serum samples from 47 mesothelioma cases and 141 matched controls were analysed. Mesothelin expression in tumors was assessed. The association between biomarker level and mesothelioma risk and survival was analysed, adjusting for asbestos exposure. Survival related to tumor mesothelin expression, age, sex, histological type, location, asbestos exposure and pre-clinical SMRP was analysed. There was no significant association between biomarker levels and mesothelioma risk when analysed as continuous variables or as tertiles. Biomarker levels <10, 10-19 and ≥20 years before diagnosis were not significantly associated to mesothelioma risk. Mesothelin expressed in >50% of tumor cells was seen in 36 of 47 (77%) tumors. Mesothelin expression in <50% of tumor cells was a significant negative prognostic marker in all cases of malignant mesothelioma (median survival=6 months vs. 12 months, hazard ratio (HR)=2.49, 95%CI 1.17-5.27), and also when only epithelial mesothelioma was analysed (median =6 months vs. 14 months, HR=2.36, 95%CI 1.07-5.22). When adjusted for age and gender, the prognosis was still dismal, but non-significant (HR=1.85, 95%CI 0.85-4.05). High age (>65 years) was an independent negative prognostic factor that was related to both mesothelin expression and asbestos exposure. Mesothelioma of the epithelial type of the peritoneum had a significantly longer survival than epithelial type in pleura and was also related to mesothelin expression.
C02	`01`	`X`		`@0 002B04`
C02	`02`	`X`		`@0 002B11A`
C03	`01`	`X`	`FRE`	`@0 Mésothéliome malin @5 01`
C03	`01`	`X`	`ENG`	`@0 Malignant mesothelioma @5 01`
C03	`01`	`X`	`SPA`	`@0 Mesotelioma maligno @5 01`
C03	`02`	`X`	`FRE`	`@0 Pathologie de l'appareil respiratoire @5 02`
C03	`02`	`X`	`ENG`	`@0 Respiratory disease @5 02`
C03	`02`	`X`	`SPA`	`@0 Aparato respiratorio patología @5 02`
C03	`03`	`X`	`FRE`	`@0 Facteur prédictif @5 09`
C03	`03`	`X`	`ENG`	`@0 Predictive factor @5 09`
C03	`03`	`X`	`SPA`	`@0 Factor predictivo @5 09`
C03	`04`	`X`	`FRE`	`@0 Pronostic @5 10`
C03	`04`	`X`	`ENG`	`@0 Prognosis @5 10`
C03	`04`	`X`	`SPA`	`@0 Pronóstico @5 10`
C03	`05`	`X`	`FRE`	`@0 Etude cas témoin @5 11`
C03	`05`	`X`	`ENG`	`@0 Case control study @5 11`
C03	`05`	`X`	`SPA`	`@0 Estudio caso control @5 11`
C03	`06`	`X`	`FRE`	`@0 Immunohistochimie @5 12`
C03	`06`	`X`	`ENG`	`@0 Immunohistochemistry @5 12`
C03	`06`	`X`	`SPA`	`@0 Inmunohistoquímica @5 12`
C03	`07`	`X`	`FRE`	`@0 Marqueur tumoral @5 13`
C03	`07`	`X`	`ENG`	`@0 Tumoral marker @5 13`
C03	`07`	`X`	`SPA`	`@0 Marcador tumoral @5 13`
C03	`08`	`X`	`FRE`	`@0 Cancérologie @5 14`
C03	`08`	`X`	`ENG`	`@0 Cancerology @5 14`
C03	`08`	`X`	`SPA`	`@0 Cancerología @5 14`
C03	`09`	`X`	`FRE`	`@0 Pneumologie @5 15`
C03	`09`	`X`	`ENG`	`@0 Pneumology @5 15`
C03	`09`	`X`	`SPA`	`@0 Neumología @5 15`
C07	`01`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 37`
C07	`01`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 37`
C07	`01`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 37`
C07	`02`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`02`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`02`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`03`	`X`	`FRE`	`@0 Anatomopathologie @5 38`
C07	`03`	`X`	`ENG`	`@0 Anatomic pathology @5 38`
C07	`03`	`X`	`SPA`	`@0 Anatomía patológica @5 38`
N21				`@1 259`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0401056 INIST
ET :	Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study
AU :	ROE (Oluf Dimitri); CREANEY (Jenette); LUNDGREN (Steinar); LARSSON (Erik); SANDECK (Helmut); BOFFETTA (Paolo); NILSEN (Tom Ivar); ROBINSON (Bruce); KJAERHEIM (Kristina)
AF :	Department of Oncology, St. Olavs Hospital, Trondheim University Hospital/Norvège (1 aut., 3 aut.); Norwegian University of Science and Technology (NTNU), Department of Cancer Research and Molecular Medicine/Trondheim/Norvège (1 aut., 3 aut.); School of Medicine and Pharmacology, University of Western Australia, QfEII Medical Centre Nedlands/Perth, Western Australia/Australie (2 aut., 8 aut.); Norwegian University of Science and Technology (NTNU), Department of Laboratory Medicine, Children's and Women's Health/Trondheim/Norvège (4 aut.); Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim University Hospital/Norvège (5 aut.); International Agency for Research on Cancer/Lyon/France (6 aut.); Norwegian University of Science and Technology (NTNU), Human Movement Science Programme/Norvège (7 aut.); The Cancer Registry of Norway/Oslo/Norvège (9 aut.)
DT :	Publication en série; Niveau analytique
SO :	Lung cancer; ISSN 0169-5002; Coden LUCAE5; Irlande; Da. 2008; Vol. 61; No. 2; Pp. 235-243; Bibl. 65 ref.
LA :	Anglais
EA :	Soluble mesothelin-related protein (SMRP) in serum is potentially a sensitive marker of malignant mesothelioma (MM) diagnosis and progression, and may be useful as screening marker. Mesothelin expression in tumors is regarded as a sensitive marker for diagnosis and disease progression, and is a candidate prognostic marker. Levels of SMRP, CA125 and CYFRA 21-1 in pre-diagnostic (1-30 years) serum samples from 47 mesothelioma cases and 141 matched controls were analysed. Mesothelin expression in tumors was assessed. The association between biomarker level and mesothelioma risk and survival was analysed, adjusting for asbestos exposure. Survival related to tumor mesothelin expression, age, sex, histological type, location, asbestos exposure and pre-clinical SMRP was analysed. There was no significant association between biomarker levels and mesothelioma risk when analysed as continuous variables or as tertiles. Biomarker levels <10, 10-19 and ≥20 years before diagnosis were not significantly associated to mesothelioma risk. Mesothelin expressed in >50% of tumor cells was seen in 36 of 47 (77%) tumors. Mesothelin expression in <50% of tumor cells was a significant negative prognostic marker in all cases of malignant mesothelioma (median survival=6 months vs. 12 months, hazard ratio (HR)=2.49, 95%CI 1.17-5.27), and also when only epithelial mesothelioma was analysed (median =6 months vs. 14 months, HR=2.36, 95%CI 1.07-5.22). When adjusted for age and gender, the prognosis was still dismal, but non-significant (HR=1.85, 95%CI 0.85-4.05). High age (>65 years) was an independent negative prognostic factor that was related to both mesothelin expression and asbestos exposure. Mesothelioma of the epithelial type of the peritoneum had a significantly longer survival than epithelial type in pleura and was also related to mesothelin expression.
CC :	002B04; 002B11A
FD :	Mésothéliome malin; Pathologie de l'appareil respiratoire; Facteur prédictif; Pronostic; Etude cas témoin; Immunohistochimie; Marqueur tumoral; Cancérologie; Pneumologie
FG :	Tumeur maligne; Cancer; Anatomopathologie
ED :	Malignant mesothelioma; Respiratory disease; Predictive factor; Prognosis; Case control study; Immunohistochemistry; Tumoral marker; Cancerology; Pneumology
EG :	Malignant tumor; Cancer; Anatomic pathology
SD :	Mesotelioma maligno; Aparato respiratorio patología; Factor predictivo; Pronóstico; Estudio caso control; Inmunohistoquímica; Marcador tumoral; Cancerología; Neumología
LO :	INIST-21159.354000196288910130
ID :	08-0401056

Links to Exploration step

Pascal:08-0401056

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study</title>
<author><name sortKey="Roe, Oluf Dimitri" sort="Roe, Oluf Dimitri" uniqKey="Roe O" first="Oluf Dimitri" last="Roe">Oluf Dimitri Roe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Oncology, St. Olavs Hospital, Trondheim University Hospital</s1>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Norwegian University of Science and Technology (NTNU), Department of Cancer Research and Molecular Medicine</s1>
<s2>Trondheim</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Creaney, Jenette" sort="Creaney, Jenette" uniqKey="Creaney J" first="Jenette" last="Creaney">Jenette Creaney</name>
<affiliation><inist:fA14 i1="03"><s1>School of Medicine and Pharmacology, University of Western Australia, QfEII Medical Centre Nedlands</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lundgren, Steinar" sort="Lundgren, Steinar" uniqKey="Lundgren S" first="Steinar" last="Lundgren">Steinar Lundgren</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Oncology, St. Olavs Hospital, Trondheim University Hospital</s1>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Norwegian University of Science and Technology (NTNU), Department of Cancer Research and Molecular Medicine</s1>
<s2>Trondheim</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Larsson, Erik" sort="Larsson, Erik" uniqKey="Larsson E" first="Erik" last="Larsson">Erik Larsson</name>
<affiliation><inist:fA14 i1="04"><s1>Norwegian University of Science and Technology (NTNU), Department of Laboratory Medicine, Children's and Women's Health</s1>
<s2>Trondheim</s2>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sandeck, Helmut" sort="Sandeck, Helmut" uniqKey="Sandeck H" first="Helmut" last="Sandeck">Helmut Sandeck</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim University Hospital</s1>
<s3>NOR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Boffetta, Paolo" sort="Boffetta, Paolo" uniqKey="Boffetta P" first="Paolo" last="Boffetta">Paolo Boffetta</name>
<affiliation><inist:fA14 i1="06"><s1>International Agency for Research on Cancer</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nilsen, Tom Ivar" sort="Nilsen, Tom Ivar" uniqKey="Nilsen T" first="Tom Ivar" last="Nilsen">Tom Ivar Nilsen</name>
<affiliation><inist:fA14 i1="07"><s1>Norwegian University of Science and Technology (NTNU), Human Movement Science Programme</s1>
<s3>NOR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Robinson, Bruce" sort="Robinson, Bruce" uniqKey="Robinson B" first="Bruce" last="Robinson">Bruce Robinson</name>
<affiliation><inist:fA14 i1="03"><s1>School of Medicine and Pharmacology, University of Western Australia, QfEII Medical Centre Nedlands</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kjaerheim, Kristina" sort="Kjaerheim, Kristina" uniqKey="Kjaerheim K" first="Kristina" last="Kjaerheim">Kristina Kjaerheim</name>
<affiliation><inist:fA14 i1="08"><s1>The Cancer Registry of Norway</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0401056</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0401056 INIST</idno>
<idno type="RBID">Pascal:08-0401056</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003363</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study</title>
<author><name sortKey="Roe, Oluf Dimitri" sort="Roe, Oluf Dimitri" uniqKey="Roe O" first="Oluf Dimitri" last="Roe">Oluf Dimitri Roe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Oncology, St. Olavs Hospital, Trondheim University Hospital</s1>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Norwegian University of Science and Technology (NTNU), Department of Cancer Research and Molecular Medicine</s1>
<s2>Trondheim</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Creaney, Jenette" sort="Creaney, Jenette" uniqKey="Creaney J" first="Jenette" last="Creaney">Jenette Creaney</name>
<affiliation><inist:fA14 i1="03"><s1>School of Medicine and Pharmacology, University of Western Australia, QfEII Medical Centre Nedlands</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Lundgren, Steinar" sort="Lundgren, Steinar" uniqKey="Lundgren S" first="Steinar" last="Lundgren">Steinar Lundgren</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Oncology, St. Olavs Hospital, Trondheim University Hospital</s1>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>Norwegian University of Science and Technology (NTNU), Department of Cancer Research and Molecular Medicine</s1>
<s2>Trondheim</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Larsson, Erik" sort="Larsson, Erik" uniqKey="Larsson E" first="Erik" last="Larsson">Erik Larsson</name>
<affiliation><inist:fA14 i1="04"><s1>Norwegian University of Science and Technology (NTNU), Department of Laboratory Medicine, Children's and Women's Health</s1>
<s2>Trondheim</s2>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Sandeck, Helmut" sort="Sandeck, Helmut" uniqKey="Sandeck H" first="Helmut" last="Sandeck">Helmut Sandeck</name>
<affiliation><inist:fA14 i1="05"><s1>Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim University Hospital</s1>
<s3>NOR</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Boffetta, Paolo" sort="Boffetta, Paolo" uniqKey="Boffetta P" first="Paolo" last="Boffetta">Paolo Boffetta</name>
<affiliation><inist:fA14 i1="06"><s1>International Agency for Research on Cancer</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nilsen, Tom Ivar" sort="Nilsen, Tom Ivar" uniqKey="Nilsen T" first="Tom Ivar" last="Nilsen">Tom Ivar Nilsen</name>
<affiliation><inist:fA14 i1="07"><s1>Norwegian University of Science and Technology (NTNU), Human Movement Science Programme</s1>
<s3>NOR</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Robinson, Bruce" sort="Robinson, Bruce" uniqKey="Robinson B" first="Bruce" last="Robinson">Bruce Robinson</name>
<affiliation><inist:fA14 i1="03"><s1>School of Medicine and Pharmacology, University of Western Australia, QfEII Medical Centre Nedlands</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kjaerheim, Kristina" sort="Kjaerheim, Kristina" uniqKey="Kjaerheim K" first="Kristina" last="Kjaerheim">Kristina Kjaerheim</name>
<affiliation><inist:fA14 i1="08"><s1>The Cancer Registry of Norway</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Lung cancer</title>
<title level="j" type="abbreviated">Lung cancer</title>
<idno type="ISSN">0169-5002</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Lung cancer</title>
<title level="j" type="abbreviated">Lung cancer</title>
<idno type="ISSN">0169-5002</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cancerology</term>
<term>Case control study</term>
<term>Immunohistochemistry</term>
<term>Malignant mesothelioma</term>
<term>Pneumology</term>
<term>Predictive factor</term>
<term>Prognosis</term>
<term>Respiratory disease</term>
<term>Tumoral marker</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Mésothéliome malin</term>
<term>Pathologie de l'appareil respiratoire</term>
<term>Facteur prédictif</term>
<term>Pronostic</term>
<term>Etude cas témoin</term>
<term>Immunohistochimie</term>
<term>Marqueur tumoral</term>
<term>Cancérologie</term>
<term>Pneumologie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Soluble mesothelin-related protein (SMRP) in serum is potentially a sensitive marker of malignant mesothelioma (MM) diagnosis and progression, and may be useful as screening marker. Mesothelin expression in tumors is regarded as a sensitive marker for diagnosis and disease progression, and is a candidate prognostic marker. Levels of SMRP, CA125 and CYFRA 21-1 in pre-diagnostic (1-30 years) serum samples from 47 mesothelioma cases and 141 matched controls were analysed. Mesothelin expression in tumors was assessed. The association between biomarker level and mesothelioma risk and survival was analysed, adjusting for asbestos exposure. Survival related to tumor mesothelin expression, age, sex, histological type, location, asbestos exposure and pre-clinical SMRP was analysed. There was no significant association between biomarker levels and mesothelioma risk when analysed as continuous variables or as tertiles. Biomarker levels <10, 10-19 and ≥20  years before diagnosis were not significantly associated to mesothelioma risk. Mesothelin expressed in >50% of tumor cells was seen in 36 of 47 (77%) tumors. Mesothelin expression in <50% of tumor cells was a significant negative prognostic marker in all cases of malignant mesothelioma (median survival=6 months vs. 12 months, hazard ratio (HR)=2.49, 95%CI 1.17-5.27), and also when only epithelial mesothelioma was analysed (median =6 months vs. 14 months, HR=2.36, 95%CI 1.07-5.22). When adjusted for age and gender, the prognosis was still dismal, but non-significant (HR=1.85, 95%CI 0.85-4.05). High age (>65 years) was an independent negative prognostic factor that was related to both mesothelin expression and asbestos exposure. Mesothelioma of the epithelial type of the peritoneum had a significantly longer survival than epithelial type in pleura and was also related to mesothelin expression.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0169-5002</s0>
</fA01>
<fA02 i1="01"><s0>LUCAE5</s0>
</fA02>
<fA03 i2="1"><s0>Lung cancer</s0>
</fA03>
<fA05><s2>61</s2>
</fA05>
<fA06><s2>2</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ROE (Oluf Dimitri)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>CREANEY (Jenette)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>LUNDGREN (Steinar)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LARSSON (Erik)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>SANDECK (Helmut)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>BOFFETTA (Paolo)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>NILSEN (Tom Ivar)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>ROBINSON (Bruce)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>KJAERHEIM (Kristina)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Oncology, St. Olavs Hospital, Trondheim University Hospital</s1>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Norwegian University of Science and Technology (NTNU), Department of Cancer Research and Molecular Medicine</s1>
<s2>Trondheim</s2>
<s3>NOR</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>School of Medicine and Pharmacology, University of Western Australia, QfEII Medical Centre Nedlands</s1>
<s2>Perth, Western Australia</s2>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Norwegian University of Science and Technology (NTNU), Department of Laboratory Medicine, Children's and Women's Health</s1>
<s2>Trondheim</s2>
<s3>NOR</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim University Hospital</s1>
<s3>NOR</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>International Agency for Research on Cancer</s1>
<s2>Lyon</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Norwegian University of Science and Technology (NTNU), Human Movement Science Programme</s1>
<s3>NOR</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>The Cancer Registry of Norway</s1>
<s2>Oslo</s2>
<s3>NOR</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>235-243</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>21159</s2>
<s5>354000196288910130</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>65 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0401056</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Lung cancer</s0>
</fA64>
<fA66 i1="01"><s0>IRL</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Soluble mesothelin-related protein (SMRP) in serum is potentially a sensitive marker of malignant mesothelioma (MM) diagnosis and progression, and may be useful as screening marker. Mesothelin expression in tumors is regarded as a sensitive marker for diagnosis and disease progression, and is a candidate prognostic marker. Levels of SMRP, CA125 and CYFRA 21-1 in pre-diagnostic (1-30 years) serum samples from 47 mesothelioma cases and 141 matched controls were analysed. Mesothelin expression in tumors was assessed. The association between biomarker level and mesothelioma risk and survival was analysed, adjusting for asbestos exposure. Survival related to tumor mesothelin expression, age, sex, histological type, location, asbestos exposure and pre-clinical SMRP was analysed. There was no significant association between biomarker levels and mesothelioma risk when analysed as continuous variables or as tertiles. Biomarker levels <10, 10-19 and ≥20  years before diagnosis were not significantly associated to mesothelioma risk. Mesothelin expressed in >50% of tumor cells was seen in 36 of 47 (77%) tumors. Mesothelin expression in <50% of tumor cells was a significant negative prognostic marker in all cases of malignant mesothelioma (median survival=6 months vs. 12 months, hazard ratio (HR)=2.49, 95%CI 1.17-5.27), and also when only epithelial mesothelioma was analysed (median =6 months vs. 14 months, HR=2.36, 95%CI 1.07-5.22). When adjusted for age and gender, the prognosis was still dismal, but non-significant (HR=1.85, 95%CI 0.85-4.05). High age (>65 years) was an independent negative prognostic factor that was related to both mesothelin expression and asbestos exposure. Mesothelioma of the epithelial type of the peritoneum had a significantly longer survival than epithelial type in pleura and was also related to mesothelin expression.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B11A</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Mésothéliome malin</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Malignant mesothelioma</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Mesotelioma maligno</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Pathologie de l'appareil respiratoire</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Respiratory disease</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Facteur prédictif</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Predictive factor</s0>
<s5>09</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Factor predictivo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>10</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Etude cas témoin</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Case control study</s0>
<s5>11</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Estudio caso control</s0>
<s5>11</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Immunohistochimie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Immunohistochemistry</s0>
<s5>12</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Inmunohistoquímica</s0>
<s5>12</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Marqueur tumoral</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Tumoral marker</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Marcador tumoral</s0>
<s5>13</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Cancérologie</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Cancerology</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Cancerología</s0>
<s5>14</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Pneumologie</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Pneumology</s0>
<s5>15</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Neumología</s0>
<s5>15</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Anatomopathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Anatomic pathology</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Anatomía patológica</s0>
<s5>38</s5>
</fC07>
<fN21><s1>259</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0401056 INIST</NO>
<ET>Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study</ET>
<AU>ROE (Oluf Dimitri); CREANEY (Jenette); LUNDGREN (Steinar); LARSSON (Erik); SANDECK (Helmut); BOFFETTA (Paolo); NILSEN (Tom Ivar); ROBINSON (Bruce); KJAERHEIM (Kristina)</AU>
<AF>Department of Oncology, St. Olavs Hospital, Trondheim University Hospital/Norvège (1 aut., 3 aut.); Norwegian University of Science and Technology (NTNU), Department of Cancer Research and Molecular Medicine/Trondheim/Norvège (1 aut., 3 aut.); School of Medicine and Pharmacology, University of Western Australia, QfEII Medical Centre Nedlands/Perth, Western Australia/Australie (2 aut., 8 aut.); Norwegian University of Science and Technology (NTNU), Department of Laboratory Medicine, Children's and Women's Health/Trondheim/Norvège (4 aut.); Department of Pathology and Medical Genetics, St. Olavs Hospital, Trondheim University Hospital/Norvège (5 aut.); International Agency for Research on Cancer/Lyon/France (6 aut.); Norwegian University of Science and Technology (NTNU), Human Movement Science Programme/Norvège (7 aut.); The Cancer Registry of Norway/Oslo/Norvège (9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Lung cancer; ISSN 0169-5002; Coden LUCAE5; Irlande; Da. 2008; Vol. 61; No. 2; Pp. 235-243; Bibl. 65 ref.</SO>
<LA>Anglais</LA>
<EA>Soluble mesothelin-related protein (SMRP) in serum is potentially a sensitive marker of malignant mesothelioma (MM) diagnosis and progression, and may be useful as screening marker. Mesothelin expression in tumors is regarded as a sensitive marker for diagnosis and disease progression, and is a candidate prognostic marker. Levels of SMRP, CA125 and CYFRA 21-1 in pre-diagnostic (1-30 years) serum samples from 47 mesothelioma cases and 141 matched controls were analysed. Mesothelin expression in tumors was assessed. The association between biomarker level and mesothelioma risk and survival was analysed, adjusting for asbestos exposure. Survival related to tumor mesothelin expression, age, sex, histological type, location, asbestos exposure and pre-clinical SMRP was analysed. There was no significant association between biomarker levels and mesothelioma risk when analysed as continuous variables or as tertiles. Biomarker levels <10, 10-19 and ≥20  years before diagnosis were not significantly associated to mesothelioma risk. Mesothelin expressed in >50% of tumor cells was seen in 36 of 47 (77%) tumors. Mesothelin expression in <50% of tumor cells was a significant negative prognostic marker in all cases of malignant mesothelioma (median survival=6 months vs. 12 months, hazard ratio (HR)=2.49, 95%CI 1.17-5.27), and also when only epithelial mesothelioma was analysed (median =6 months vs. 14 months, HR=2.36, 95%CI 1.07-5.22). When adjusted for age and gender, the prognosis was still dismal, but non-significant (HR=1.85, 95%CI 0.85-4.05). High age (>65 years) was an independent negative prognostic factor that was related to both mesothelin expression and asbestos exposure. Mesothelioma of the epithelial type of the peritoneum had a significantly longer survival than epithelial type in pleura and was also related to mesothelin expression.</EA>
<CC>002B04; 002B11A</CC>
<FD>Mésothéliome malin; Pathologie de l'appareil respiratoire; Facteur prédictif; Pronostic; Etude cas témoin; Immunohistochimie; Marqueur tumoral; Cancérologie; Pneumologie</FD>
<FG>Tumeur maligne; Cancer; Anatomopathologie</FG>
<ED>Malignant mesothelioma; Respiratory disease; Predictive factor; Prognosis; Case control study; Immunohistochemistry; Tumoral marker; Cancerology; Pneumology</ED>
<EG>Malignant tumor; Cancer; Anatomic pathology</EG>
<SD>Mesotelioma maligno; Aparato respiratorio patología; Factor predictivo; Pronóstico; Estudio caso control; Inmunohistoquímica; Marcador tumoral; Cancerología; Neumología</SD>
<LO>INIST-21159.354000196288910130</LO>
<ID>08-0401056</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003363 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003363 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0401056
   |texte=   Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study

Mesothelin-related predictive and prognostic factors in malignant mesothelioma : A nested case-control study

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri